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Ischemia/reperfusion (I/R) of several organs results in complement activation, but the kidney is unique in
that activation after I/R occurs only via the alternative pathway. We hypothesized that selective activation of
this pathway after renal I/R could occur either because of a loss of complement inhibition or from increased
local synthesis of complement factors. We examined the relationship between renal complement activation
after I/R and the levels and localization of intrinsic membrane complement inhibitors. We found that loss
of polarity of complement receptor 1–related protein y (Crry) in the tubular epithelium preceded activation
of the alternative pathway along the basolateral aspect of the tubular cells. Heterozygous gene-targeted mice
that expressed lower amounts of Crry were more sensitive to ischemic injury. Furthermore, inhibition of Crry
expressed by proximal tubular epithelial cells in vitro resulted in alternative pathway–mediated injury to the
cells. Thus, altered expression of a complement inhibitor within the tubular epithelium appears to be a critical factor permitting activation of the alternative pathway of complement after I/R. Increased C3 mRNA and
decreased factor H mRNA were also detected in the outer medulla after I/R, suggesting that altered synthesis
of these factors might further contribute to complement activation in this location.
*OUSPEVDUJPO
Complement activation has been shown to be an important event
in the development of ischemic acute renal failure (ARF) in mice.
Studies in complement-deficient mice have shown that these mice
are protected from renal failure after ischemia/reperfusion (I/R)
(1, 2), and that generation of the anaphylatoxin C5a (3) and the
membrane attack complex (2) may contribute to the pathogenesis
of ischemic ARF. Treatment with agents that inhibit the complement cascade at specific steps during the activation cascade has
proven effective at ameliorating ischemic ARF (3, 4). Determining
the initiating mechanisms of complement activation after renal
I/R is essential to the effective use of complement inhibitors for
the treatment and prevention of ischemic ARF.
Complement activation after renal I/R occurs via the alternative pathway (1) and is independent of natural antibody (5). In
contrast, I/R injury of other organs such as the heart, intestine,
and skeletal muscle appears to involve activation of the classical
pathway of complement. Complement activation after intestinal
I/R, for example, is the result of natural antibodies that bind to
neoantigens exposed within the ischemic bowel (6, 7). Cardiac
I/R also appears to involve classical pathway activation by antibodies that recognize newly exposed antigens (8). Renal I/R therefore involves unique mechanisms of complement activation.
Nonstandard abbreviations used: ARF, acute renal failure; ATN, acute tubular
necrosis; Crry, complement receptor 1–related protein y; DAF, decay-accelerating factor; I/R, ischemia/reperfusion; LDH, lactate dehydrogenase; PTEC, proximal tubular
epithelial cell; SUN, serum urea nitrogen.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 116:357–368 (2006). doi:10.1172/JCI24521.
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The alternative pathway is ordinarily activated at low levels via
an enzymatic process, called “tickover,” which results in continuous low-level production of C3b. When C3b binds covalently to an
activating surface, such as a bacterial cell wall, it is stabilized such
that it can combine with factor B to create the alternative pathway
C3 convertase. Such activation of the alternative pathway does not
usually cause injury to self cells due to the presence of membranebound and fluid-phase complement regulatory proteins (9). These
inhibitors are essential to prevent complement-mediated injury
to the host, and deficiency of complement inhibitors can lead to
spontaneous injury. For example, humans, pigs, and mice deficient
in the fluid-phase factor H spontaneously develop membranoproliferative glomerulonephritis (10), the expression of dysfunctional
CD46 is associated with development of the hemolytic uremic
syndrome (11, 12), and paroxysmal nocturnal hemoglobinuria is
associated with deficiencies of decay-accelerating factor (DAF, also
known as CD55) and CD59 (13).
Local synthesis of complement components has also emerged
as an important cause of complement activation and tissue injury
in some models. For instance, in a murine renal transplant model,
synthesis of C3 by the kidney was found to contribute to complement activation within the tubulointerstitium and, as opposed to
serum C3, to be essential to graft loss (14).
Renal I/R in the mouse (1) and in humans (15) leads to the
marked deposition of complement activation products along
the tubular basement membrane. Although several inhibitors
of complement activation are present within the mouse kidney,
only complement receptor 1–related protein y (Crry) is present on
mouse tubular epithelial cells (16), the cells primarily injured during I/R. DAF and CD59 expression is limited to the glomeruli and
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the tubules. Furthermore, C3 mRNA was increased and factor H
mRNA was decreased in the outer medulla after I/R, indicating
that altered synthesis of these factors might further contribute to
alternative pathway activation at this location. Understanding the
mechanisms whereby intrinsic complement inhibitors are unable
to control activation may help in the rational use of complement
inhibitors as therapeutics for the prevention of ischemic ARF.
These studies may also further our understanding of more general
inflammatory responses to injury.
3FTVMUT
Localization of intrinsic complement inhibitors within the kidney. Frozen
sections of kidneys from unmanipulated mice were examined by
immunofluorescence to determine the localization of the membrane-bound complement inhibitors. Consistent with previous
reports (14), Crry was heavily expressed within the glomeruli as
well as the tubules (Figure 1). Crry in the proximal tubules was
polarized to the basolateral surface of the epithelial cells. Expression was contained within the basement membrane, and no Crry
was detectable within the cytoplasm or brush border. To further
evaluate Crry expression by proximal tubular cells, immunogold
labeling and evaluation by electron microscopy were performed
on rat kidneys (Figure 2). Labeling within both the apical (34 ± 4
particles/field, n = 22 fields) and basal regions (67 ± 8 particles/
field, n = 19 fields) was significantly above background labeling with nonimmune serum (12 ± 2 particles/field, n = 10 fields;
P < 0.01 versus apical P < 0.001 versus basal labeling with anti-Crry,

renal arteries (17, 18). Deficiency in DAF alone or DAF and CD59
results in vascular complement activation after I/R and worse
renal injury (19, 20). However, substantial vascular complement
activation does not occur in wild-type mice after I/R (2). Therefore,
in the normal host these particular inhibitors must retain their
function, preventing further injury. In contrast, the activation of
complement along the tubular basement membrane of wild-type
mice after I/R suggests that local inhibition by Crry is either hindered or overwhelmed.
Given the importance of membranebound Crry for the prevention of alternative
pathway complement activation and tubular
injury, we hypothesized that altered expression or localization of Crry by tubular epithelial cells might contribute to the activation of complement after I/R, or that local
synthesis of complement C3 or factor B in
response to I/R could overwhelm tubularintrinsic Crry. Therefore, we set out to study
the effects of renal ischemia upon Crry and
the relation of changes in Crry expression,
'JHVSF
local synthesis of complement components,
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unpaired Student’s t test). Labeling in the region of the basolateral
cell surface was significantly higher than that within the apical
brush border (P < 0.001, unpaired Student’s t test). As previously
reported (17, 18), DAF and CD59 were expressed within the glomeruli and vasculature, but not in the tubules (Figure 1).
Complement activation is an early event after renal I/R. Mice were
subjected to 24 minutes of bilateral renal ischemia or sham surgery and were sacrificed after 0, 2, 6, 24, and 48 hours of reperfusion. Serum was collected for serum urea nitrogen (SUN) measurements, and kidneys were evaluated for tubular injury and
complement C3 deposition. Consistent with previous reports,
sham-treated animals demonstrated small areas of C3 deposition
(Figure 3A) along the tubular basement membrane of approximately 10–15% of the tubules in the cortex and outer stripe of
the outer medulla (1, 21).
When tubules within the outer medulla were examine by fluorescent microscopy, a significant increase in the percentage of tubules
showing complement deposition along the tubular basement
membrane was seen by 6 hours of reperfusion (Figure 3A), similar to results previously reported by other groups (22). The degree
of tubules showing complement deposition peaked at 24 hours of
reperfusion, involving 46–75% of the tubules, and returned to baseline by 48 hours of reperfusion. Western blot analysis of total kidThe Journal of Clinical Investigation

ney lysates demonstrated a clear increase in complement activation
products after ischemia and 24 hours of reperfusion (Figure 3D).
Although some epithelial cell swelling and brush border injury
were evident within 6 hours of reperfusion (Figure 3B), the acute
tubular necrosis (ATN) grade did not significantly increase until
after 24 hours of reperfusion and returned to baseline by 48
hours of reperfusion (Figure 3B). Thus, complement activation
is an early event that precedes severe morphological injury after
I/R. Although SUN levels did not significantly increase until after
24 hours of reperfusion (Figure 3C), this was expected because
serum markers do not reflect changes in renal function until a
new steady state is reached.
Crry levels in the whole kidney do not significantly change after I/R. Crry
is present in multiple isoforms in the kidney (23). Analysis of protein from immortalized proximal tubular epithelial cells (PTECs)
by Western blot revealed that most of the Crry in proximal tubular
cells was of the 53-kDa isoform (Figure 4A). Protein from rat kidneys demonstrated that 53-kDa Crry was present in basolateral
membrane–enriched fractions but not in brush border–enriched
fractions (Figure 4B). Blotting for type IIa Na/Pi cotransporter,
which is known to be expressed on the apical brush border, was
stronger on the brush border–enriched fraction. As further evidence that it is the 53-kDa isoform that is expressed by PTECs, the
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other 2 Crry isoforms were not detected in the basolateral membrane–enriched fraction. When protein was isolated from wholekidney sections, little difference in overall levels of Crry was discerned (Figure 4C), likely due to the fact that Crry is expressed in
glomeruli and in tubules throughout the kidney. However, a trend
toward decreased expression of the 53-kDa isoform was seen after
6 hours of reperfusion. Semi-quantitative PCR was performed on
tissue isolated from the outer medulla (Figure 4D). A trend toward
increased mRNA for Crry was seen after 6 hours of reperfusion.
Altered Crry localization precedes complement activation. As discussed
above, Crry is the only complement inhibitor expressed on the surface of renal tubules. At baseline, Crry was polarized to the basolateral aspect of the renal tubules (Figure 1), abutting the site of
occasional focal C3 deposition along the tubular basement membrane (Figure 5A). In kidneys subjected to 24 minutes of ischemia
this polarity was lost before reperfusion, and Crry could be seen
within the tubule lumen (Figure 5B). As shown in Figure 3, the
tubules showed signs of injury at these early time points but did
not yet show necrosis. The altered Crry expression is therefore a
biochemical change of non-necrotic tubules. After 6 and 24 hours
of reperfusion (Figure 5, C and D), individual tubules demonstrated little remaining Crry. Those tubules that no longer demonstrated Crry expression had C3 deposited along their circumference. By
48 hours of reperfusion Crry still appeared in the cytosol but was
also seen concentrated at the basolateral surface, and complement
deposition had nearly returned to baseline (Figure 5E).
Because Crry appeared in the tubular lumen after ischemia, we
examined the urine for the presence of Crry. It is known that PTECs
shed F-actin–containing membrane vesicles into the tubular lumen
after I/R (24). We found that the urinary sediment of mice subjected
to I/R contained both F-actin and Crry (Figure 5F). This indicates
that loss of Crry in the blebs and vesicles shed in the urine after I/R
partially accounts for the absence of Crry in some tubular segments.
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Lower-powered views of kidneys stained for Crry and C3 demonstrated that Crry and C3 did not colocalize along the tubules. At
baseline (Figure 6A), Crry was polarized to the basolateral aspect
of tubules, and sporadic patches of C3 were seen along the tubular
basement membrane. Little colocalization (yellow) was seen.
In order to quantitate colocalization of Crry and C3, we performed
digital microscopy and measured the color intensity at each wavelength (Figure 6, D and E). Pixels were plotted according to their
Crry and C3 intensity, and the number of pixels within the image
that had a given staining intensity was indicated by color. A histogram of Crry and C3 intensity (Figure 6D) showed that there was
virtually no colocalization of C3 and Crry. Pixels with a high intensity of both markers would map to the upper right quadrant. Very
few pixels were present within this quadrant, indicating that those
pixels with a high intensity for Crry staining did not have abundant C3. After 24 hours of reperfusion (Figure 6, C and E) there was
much greater overall C3 deposition than at baseline, but there was
still little, if any, colocalization of C3 and Crry. Renal I/R injury is
patchy in nature, and some tubules retained their polarity (Figure
6C, arrows) even in areas of extensive injury. Consistent with the
histogram in Figure 6E, those tubules that retained the polarity of
Crry showed little C3 deposition, whereas those with more severely
altered Crry localization showed extensive C3 deposition.
Our results demonstrate that Crry localization was altered
during renal ischemia prior to complement deposition and that
tubules that retained Crry expression showed little C3 deposition.
These data suggest that altered Crry localization is permissive of
complement activation and that altered complement inhibition is
a necessary event in the activation of complement after renal I/R.
Although overall expression of Crry in the kidney did not significantly decrease (Figure 4), altered expression of Crry specifically on
the surface of the tubules appeared to permit complement activation at that specific location.
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Altered Crry localization occurs primarily in the proximal tubule. Dual
staining of kidney sections for Crry and a distal tubule marker
revealed that altered Crry localization occurred primarily in proximal tubules (Figure 7A). It has long been known that Na/K-ATPase,
another protein polarized to the basolateral aspect of PTECs, is
associated with the actin cytoskeleton. Many studies have shown
that I/R causes Na/K-ATPase to lose its polarity, and that after I/R
the protein is seen diffusely throughout the cell cytoplasm (25,
26). Dual staining for Crry and Na/K-ATPase demonstrated that

these proteins colocalized to the basolateral membrane of proximal tubules at baseline (Figure 7B). After I/R both shifted into the
cytoplasmic domain. Colocalization of the proteins was weaker
after I/R, however, suggesting distinct subcellular localizations.
Crry shifts from a triton-insoluble to a triton-soluble form after I/R. The
polarity of many transmembrane proteins is maintained by attachment to the actin cytoskeleton (27), an association that can render a
protein triton insoluble. A change in a renal tubular protein’s solubility in triton after I/R may therefore reflect the disruption of this
cytoskeletal attachment (25). To explore the possibility that tubular
Crry is attached to the cytoskeleton, we examined the triton solubility of Crry before and after I/R. At baseline, approximately half of
the 53-kDa Crry isoform was present in the triton-extractable fraction of whole-kidney sections (Figure 7C). After I/R, however, nearly
all of the protein was present in the triton-soluble fraction. The
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/B,"51BTF SFE EFNPOTUSBUFEUIBUCPUIXFSF
QPMBSJ[FEQSPUFJOTUIBUDPMPDBMJ[FEBUCBTFMJOFUPUIF
CBTPMBUFSBMBTQFDUPGQSPYJNBMUVCVMFT ZFMMPX "GUFS
JTDIFNJBBOEIPVSTPGSFQFSGVTJPOUIFQPMBSJUZPG
CPUIQSPUFJOTXBTMPTU BOECPUIBQQFBSFEEJTQFSTFE
UISPVHIPVU UIF DZUPQMBTNJD EPNBJO $  1SPUFJO
XBTFYUSBDUFEGSPNLJEOFZTBUCBTFMJOFBOEBGUFS
JTDIFNJBBOEIPVSTPGSFQFSGVTJPOVTJOHB5SJUPO
9mDPOUBJOJOHMZTJTCVGGFS'SBDUJPOTPGUSJUPOTPM
VCMF 4 BOEJOTPMVCMF * QSPUFJOXFSFTFQBSBUFECZ
4%41"(&BOECMPUUFEGPS$SSZ5IFL%BGPSNPG
$SSZXBTEFUFDUBCMFJOUIFUSJUPOJOTPMVCMFGSBDUJPOBU
CBTFMJOF BOEUIFSBUJPPGUSJUPOJOTPMVCMFUPTPMVCMF
$SSZXBTHSFBUFSUIBO"GUFSJTDIFNJBBOEIPVST
PGSFQFSGVTJPO PWFSPGUIF$SSZIBECFDPNF
USJUPOTPMVCMF 1WFSTVTCBTFMJOF0SJHJOBM
NBHOJGJDBUJPO ×

other isoforms, in contrast, were primarily triton insoluble in both
nonischemic and postischemic samples. This supports the hypothesis that the polarization of 53-kDa Crry in tubular epithelial cells is
dependent upon attachment to the cytoskeleton, and the disruption
of this attachment explains the loss of polarity seen after I/R.
Deficiency of Crry renders mice susceptible to renal I/R injury. To confirm that the loss of inhibition by Crry is an important event in the
pathogenesis of ischemic ARF and complement activation, we subjected Crry-deficient and wild-type mice to a milder renal insult
(Figure 8). Crry+/– mice do not directly address the issue of redistribution per se. They do, however, address the issue of the “concentration” of the complement inhibitor at the site of activation. We
hypothesized that loss of functional Crry at the basolateral tubule
would render the tubules more susceptible to injury, whether due
to redistribution, targeted gene deletion, or the exogenous administration of an inhibitor of Crry (28). We therefore predicted that
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mice expressing less Crry at this location in the
first place are more susceptible to complement
activation. When subjected to 20 minutes of ischemia and 24 hours of reperfusion, Crry+/– mice
had significantly greater SUNs (111 ± 18 versus
52 ± 8 mg/dl; P < 0.01) and significantly greater
morphological injury (average ATN score, 3.9 ± 0.3
versus 2.56 ± 0.6; P < 0.05) than did wild-type controls. Thus, mice that express decreased levels of
Crry develop more severe injury in response to a
mild ischemic insult.
Crry is critical for protecting PTECs in culture from
alternative pathway–mediated injury. Complement
activation may injure the tubular epithelium
directly or through indirect effects such as alterations to the vasculature or chemotaxis of inflammatory cells. In order to confirm that PTECs
themselves are the direct target of local alternative
pathway–mediated injury when Crry function is impaired, we developed an in vitro model of PTEC injury. We incubated PTECs with
fresh mouse serum in a buffer solution containing 10 mM EGTA
in order to inhibit classical pathway activation. Treatment of these
cells with an inhibitory rat IgG1 mAb to Crry in order to suppress
the function of this protein caused injury to the cells as assessed by
lactate dehydrogenase (LDH) release (Figure 9), whereas the addition of control rat IgG1 had no effect. Similar injury was also seen
when Fab fragments of the inhibitory antibody were used, indicating that the injury is not a nonspecific effect of antibody binding
or Fc-mediated complement activation. We then added the same
inhibitor to a reaction mix in which the alternative complement
pathway was selectively blocked with a mAb to factor B. Without
an intact alternative pathway, blocking the function of Crry did not
result in injury to the cells. Thus, functional Crry on the surface of
PTECs is essential to the prevention of alternative pathway–mediat-
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$SSZEFGJDJFOUNJDFBSFNPSFTVTDFQUJCMFUP*3JOKVSZUIBOXJMEUZQF
DPOUSPMT " ,JEOFZMZTBUFTGSPN$SSZ mNJDFBOEXJMEUZQFDPOUSPMT
XFSFCMPUUFEGPS$SSZ EFNPOTUSBUJOHUIBUUIF$SSZ mNJDFFYQSFTTFE
BQQSPYJNBUFMZ IBMG UIF QSPUFJO PG XJMEUZQF DPOUSPMT $SSZ m NJDF
TIPXFETJHOJGJDBOUMZHSFBUFSJODSFBTFTJO46/ # BOENPSQIPMPHJDBM
JOKVSZ $ DPNQBSFEXJUIDPOUSPMNJDFBGUFSNJOVUFTPGJTDIFNJBBOE
IPVSTPGSFQFSGVTJPO %BOE& 3FQSFTFOUBUJWFJNBHFTGSPNUIF
PVUFSTUSJQFPGUIFPVUFSNFEVMMBJOXJMEUZQF % BOE$SSZ m & NJDF
BGUFS*3EFNPOTUSBUFEUIBUUVCVMBSJOKVSZ BSSPXT XBTNPSFFYUFOTJWF
JOUIF$SSZ mNJDF0SJHJOBMNBHOJGJDBUJPO ×

ed cellular injury. As described above, Crry was the only membranebound inhibitor of complement expressed by PTECs. The loss of
complement inhibition by Crry on the surface of PTECs, whether
by the application of an inhibitor of this protein in vitro or by the
altered expression of Crry after ischemia, is therefore sufficient to
permit alternative pathway–mediated injury of the cells.
Local synthesis of alternative pathway components after I/R. In other
models, local synthesis of complement by the kidney has been
found to be an important cause of complement activation and
tissue injury (14). The kidney has been shown capable of synthesizing C3, factor B, and factor H (29, 30), and renal I/R in rats
was demonstrated to increase renal C3 expression (31). To determine whether the complement activation that occurs after I/R
is enhanced by local synthesis of alternative pathway substrates,

mice were subjected to sham surgery or to I/R. After variable
times of reperfusion, the outer medulla (where C3 deposition is
heaviest) was dissected out, and real-time PCR was performed to
quantitate expression of C3, factor B, and factor H (Figure 10). C3
mRNA did not significantly increase at any of the times of reperfusion, although at 24 hours there was a trend toward increased
C3 mRNA. Because of the tendency toward increased C3 synthesis
after I/R, we more specifically evaluated the tubules of the outer
medulla for changes in C3 synthesis using in situ hybridization
(Figure 10). Local synthesis of C3 was evident in the outer medullas of sham-treated animals, and synthesis in this region increased
after 24 hours of reperfusion. Factor H mRNA in the outer medulla was significantly decreased from baseline after 2 and 24 hours of
reperfusion, as determined by real-time PCR. Thus increased local
synthesis of C3 and decreased synthesis of factor H may further
facilitate alternative pathway activation during reperfusion. Given
the basal synthesis of C3 in this region of the kidney, it is also possible that a pool of locally produced C3 contributes to the activation that occurs after I/R. Furthermore, even small increases in
C3 synthesis may serve to initiate a much larger degree of complement activation, subsequently utilizing circulating components of
the alternative pathway.
%JTDVTTJPO
Complement activation by the alternative complement pathway is
an important pathogenic event after I/R (1, 2). C3 deposition primarily occurs along the tubular basement membrane of proximal
tubules in the outer stripe of the outer medulla, and Crry is the
only membrane-bound inhibitor of complement expressed by the
tubular epithelial cells in this segment of the nephron. At baseline,
Crry is polarized to the basolateral aspect of the tubules, adjacent
to where complement deposition occurs after I/R. Mice that are

'JHVSF
*OUBDU$SSZGVODUJPOJTOFDFTTBSZUPQSFWFOUJOKVSZUP15&$TCZBMUFS
OBUJWFQBUIXBZDPNQPOFOUTQSFTFOUJONPVTFTFSVN15&$TXFSF
JODVCBUFEXJUIGSFTINPVTFTFSVNJOUIFQSFTFODFPSBCTFODFPG% 
BOJOIJCJUPSZN"CUP$SSZ8IFOJODVCBUFEXJUI% UIFBEEJUJPOPG
TFSVNUPUIF15&$TSFTVMUFEJO-%)SFMFBTFCZUIFDFMMT5IFBEEJUJPO
PGDPOUSPM*H( JODPOUSBTU EJEOPUJOKVSFUIFDFMMT5IFBEEJUJPOPGUIF
N"C BTQFDJGJDJOIJCJUPSGPSGBDUPS#PGUIFBMUFSOBUJWFQBUIXBZ 
QSFWFOUFEUIFSFMFBTFPG-%)CZDFMMTJODVCBUFEXJUI%BOETFSVN
5IFSFBDUJPOTXFSFDPOEVDUFEXJUIN.&(5"UPQSFWFOUBDUJWBUJPO
PGUIFDMBTTJDBMQBUIXBZCZUIFBOUJCPEZ5IFFYQFSJNFOUXBTSFQFBUFE
VTJOH*H(BOE'BCGSBHNFOUTPGUIF%BOUJCPEZ BOE-%)SFMFBTF
XBTTJNJMBSJOUIFHSPVQT
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loss of a stabilizing association, such
as with the actin cytoskeleton. The
rapid change in the triton solubility of Crry and movement of it away
from the basolateral membrane preceded detectable activation of complement on the tubular cells.
Treatment with an inhibitor of
Crry leads to increased complement
activation and spontaneous tubular injury in rats (28). Furthermore,
we have found that mice expressing
lower levels of Crry (Crry+/– mice)
were more susceptible to renal I/R.
This supports the hypothesis that a
decreased concentration of Crry at
the basolateral aspect of the PTEC
(whether due to a targeted gene
'JHVSF
-PDBMTZOUIFTJTPGDPNQMFNFOUDPNQPOFOUTXJUIJOUIFLJEOFZBGUFS*35IFPVUFSNFEVMMBXBTEJT mutation, the administration of
TFDUFEPVUGSPNVONBOJQVMBUFELJEOFZTBOELJEOFZTTVCKFDUFEUPJTDIFNJBBOEWBSJBCMFUJNFTPG an exogenous inhibitor, or altered
SFQFSGVTJPON3/"XBTJTPMBUFEGSPNUIFTFTBNQMFT BOERVBOUJUBUJWFSFBMUJNF1$3XBTQFSGPSNFE expression in response to I/R) leaves
UPBTTFTTDIBOHFTJOUIFMPDBMTZOUIFTJTPGUIFDPNQMFNFOUDPNQPOFOUT$ " GBDUPS# G# #  the tubules more susceptible to comPSGBDUPS) G) $ BGUFS*35IFTFDPNQPOFOUTXFSFFYQSFTTFEBUMPXMFWFMTXJUIJOVONBOJQVMBUFE plement-mediated injury. When the
LJEOFZT"USFOEUPXBSEJODSFBTFE$XBTTFFOBGUFSIPVSTCVUEJEOPUSFBDITUBUJTUJDBMTJHOJGJ
function of Crry expressed by PTECs
DBODF4JHOJGJDBOUEFDSFBTFTJOGBDUPS)TZOUIFTJTXFSFPCTFSWFEBGUFSBOEIPVSTPGSFQFSGVTJPO
in culture was blocked, the cells were
1WFSTVTTIBNUSFBUNFOU  %BOE& *OTJUVIZCSJEJ[BUJPOGPS$EFNPOTUSBUFEUIBU$
N3/" BSSPXT XBTEFUFDUBCMFJOUIFPVUFSNFEVMMBPGTIBNUSFBUFEBOJNBMT % CVUMFWFMTXFSF injured in the presence of alternative
NVDIIJHIFSBGUFSJTDIFNJBBOEIPVSTPGSFQFSGVTJPO & )ZCSJEJ[BUJPOPGTIBN OPUTIPXO BOE pathway–sufficient serum. Blocking
QPTUJTDIFNJD ' LJEOFZTXJUIBTFOTFQSPCFGPS$XFSFQFSGPSNFEBTOFHBUJWFDPOUSPMT*OTJUV the function of Crry did not injure
IZCSJEJ[BUJPOXBTQFSGPSNFEPOBOJNBMTQFSHSPVQ BOESFQSFTFOUBUJWFJNBHFTBSFTIPXO
PTECs when the alternative complement pathway in the serum to which
they were exposed was also inhibited.
deficient in DAF and CD59 are susceptible to complement-medi- This confirms the importance of Crry for the prevention of autoloated injury after renal I/R (19, 20), likely due to complement acti- gous complement-mediated tubular injury. Loss of this protection,
vation along the vascular endothelium (19). However, extensive due to either congenital deficiency, exogenous inhibition, or loss
complement activation after I/R in wild-type mice occurs along of polarity after I/R, permits uncontrolled activation of the alterthe tubular epithelium. Thus, I/R must cause the Crry expressed native pathway on the surface of tubular epithelial cells. A study
by these cells to become overwhelmed.
in which exogenous Crry-Ig was administered to mice before they
We have demonstrated herein that ischemia quickly led to altered underwent I/R did not find that this agent significantly protected
localization of Crry. Even before reperfusion of the kidney began, the mice from ARF (32). All of the mice in this study were also
Crry shifted away from the basolateral membrane and into the cyto- treated with heparin, however, and heparin is a very effective complasm. Although levels of Crry in the whole kidney remained close plement inhibitor (33). It is therefore likely that heparin inhibited
to baseline after I/R, immunofluorescence demonstrated that levels complement activation in both experimental groups, obscuring
of the protein in proximal tubules in the outer stripe of the outer any potential benefit derived from Crry-Ig.
medulla were much lower within 6 hours of reperfusion, and CrryPrevious studies have shown that PTECs in culture activate the
containing blebs appeared in the urine after I/R. A trend toward alternative pathway when they are heat killed (34), and that such
increased Crry mRNA in the outer medulla suggests that replace- activation results in an inflammatory response by the cells (35).
ment of the lost Crry by the repaired kidney is accomplished by syn- It is possible that altered expression of Crry is a general response
thesis of new protein. Complement deposition along the tubules to injury of these cells, and that complement activation by tubuoccurred only after the loss of Crry at this location. Despite abun- lar epithelial cells also occurs in other forms of tubular injury. In
dant C3 deposition after I/R there was little colocalization of C3 support of this, we have observed that glycerol-induced rhabdoand Crry, suggesting that the loss of Crry at the basolateral surface myolysis (a model of toxin-induced ATN) is also characterized
is necessary for activation of the alternative pathway. Conversely, by decreased tubular Crry and peritubular C3 deposition (our
those tubules that retained polarized expression of Crry along their unpublished observations).
surface demonstrated little C3 deposition.
We have examined the effects of I/R on the intrinsic inhibitors
Crry is analogous to other polarized membrane-associated pro- of complement activity and on local synthesis of the complement
teins such as Na/K-ATPase, which has long been known to lose its components. Several previous studies have highlighted the conpolarity during ischemia (25). Like Na/K-ATPase, Crry within the tribution of locally synthesized C3 to the development of renal
kidney also shifted from a triton-insoluble fraction to an almost injury (14, 31). Real-time PCR of samples made from the outer
entirely triton-soluble state during ischemia. As is the case with medulla demonstrated that there was basal synthesis of C3 in this
Na/K-ATPase, this biochemical shift of Crry probably reflects the region, and synthesis of C3 was increased after I/R when evaluated
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5BCMF
Gene-specific primers and probes

Membrane cofactor protein (MCP, also
known as CD46 ), a human functional analog of Crry, is expressed by human PTECs
in a polarized fashion (38). Studies have
Primer
Sequence
demonstrated that the polarity of PTECs
C3 for
5′-GGAAACGGTGGTGGAGAAAGC-3′
is disrupted in human ATN (39). Loss of
C3 rev
5′-CTCTTGACAGGAATGCCATCGG-3′
Factor B for
5′-CTCGGGCTCCATGAATATCTACC-3′
polarity of MCP after I/R may also thereFactor B rev
5′-CCGTAACTCGCCACCTTCTC-3′
fore occur, permitting activation of the
Factor H for
5′-GAGCCTGAGACCCAACTTCC-3′
alternative pathway.
Factor H rev
5′-CTGTGCAACGAAGGTACTCC-3′
Our results may also have broader impliCyclophilin for
5′-TGGAGAGCACCAAGACAGACA-3′
cations regarding the regulation of compleCyclophilin rev
5′-TGCCGGAGTCGACAATGAT-3′
ment activation. The importance of the
Crry for
5′-AGTGGATTCCTTGTGAGATACCC-3′
complement system in the pathogenesis
Crry rev
5′-TTGAGTTCAATGCACTGAGGAGG-3′
of immune complex diseases as well as the
GAPDH for
5′-CCATGGAGAAGGCCGGG-3′
mechanisms of complement activation
GAPDH rev
5′-CAAAGTTGTCATGGATGACC-3′
in these diseases are well established. The
C3 antisense probe 5′-GTCGATGGCGATGAGGTTGGCAGCTAGAGAGAAGACCTTGACCACGTA-3′
complement system has recently been impliGPS GPSXBSESFW SFWFSTF
cated in a large number of Ig-independent
diseases (40–42), however, and the cause of
activation in these diseases has yet to be fully
by in situ hybridization. In contrast, local synthesis of factor H elucidated. Although genetic complement deficiencies are known
was decreased after I/R. Thus, I/R causes a shift toward greater C3 to cause autoimmune disease (10, 13), nongenetically determined
production and decreased factor H synthesis in the outer medulla loss of complement inhibition of a specific organ or cell type may
significantly contribute to inflammation and organ injury. Studduring the period when Crry expression is most disrupted.
It is possible that I/R of the kidney results in the generation of ies in rats have shown that CD59 expression in the myocardium
specific alternative pathway activators. Moieties such as endo- decreases after ischemia, perhaps allowing greater assembly of the
toxin, IgA, ammonia, and nephritic factor can cause activation of membrane attack complex (43), although in that setting complethe alternative pathway. We have conducted experiments in which ment activation precedes loss of inhibition. Anoxic injury of human
mice were fed water containing potassium bicarbonate or ammo- endothelial cells in culture also results in diminished expression of
nium chloride in an effort to alter the renal ammonia content cell surface complement inhibitors and activation of the compleand therefore alter the magnitude of complement activation after ment system on the cell surface (44). Given the need for constant
I/R. These manipulations did not detectably affect the degree of inhibition of the alternative pathway to prevent spontaneous injucomplement activation in the kidney either before or after I/R (our ry, it is possible that other injuries in various tissues may impede
unpublished observations). Although the presence of ammonia this tonic inhibition and result in alternative pathway activation.
may be an important component of peritubular alternative path- Locations such as the renal tubules that rely on only 1 complement
way activation, changes in local ammonia content do not explain inhibitor may be particularly vulnerable to such injuries.
We have demonstrated that altered localization and expression of
the increase in complement activation seen after I/R. There are no
obvious mechanisms for accumulation of the other known alter- renal tubular epithelial Crry is an early consequence of renal ischnative pathway activators in this model, but we have not excluded emia. The loss of inhibition by Crry is permissive of complement
the possibility that ischemic tubular epithelial cells generate and activation on the surface of epithelial cells and of the resultant comrelease proteases that could contribute to this process.
plement-mediated injury. These results explain the unique nature
The polarization of proteins within renal epithelia is essential to of complement activation in the kidney after I/R. Furthermore,
the proper function of the kidney. Molitoris et al. (36) demonstrated these findings demonstrate that complement activation may be a
that the basolateral polarization of Na/K-ATPase is lost after I/R. response to any injury that alters host expression of complement
Disruption of the polarized organization of proteins within the inhibitors. Inhibition of the alternative pathway may be an effecplasma cell membrane results in the loss of vectorial transport tive means of ameliorating ischemic ARF. The loss of complement
across the epithelium, loss of tight junctions between epithelial inhibition and the activation of the alternative pathway are early
cells, and loss of integrin-mediated adhesion of epithelial cells to events after I/R, however, and exogenous inhibition may need to be
the extracellular matrix (37). Our results demonstrate that the loss performed soon after the ischemic event. The exact localization of
of polarized expression of Crry renders the epithelial cells prone to cell surface complement inhibitors is clearly very important, and
complement activation and further injury. Furthermore, the genera- exogenous inhibitors of complement may not effectively prevent
tion of proinflammatory complement activation products such as activation of complement on the epithelial cell surface if they do
the anaphylatoxin C5a or the generation of other proinflammatory not achieve adequate levels specifically at this site.
cytokines caused by uncontrolled complement activation along the
tubular epithelium (35) may have widespread and deleterious conse- .FUIPET
quences for the host. Insults to the precise organization of the tubu- Experimental animals. C57BL/6J mice (The Jackson Laboratory) were used
lar epithelium therefore impair renal function as well as contribute as wild-type mice for experiments examining the relationship of Crry
to the local, and possibly systemic, inflammatory response.
expression and complement activation. Crry-deficient mice were generWe previously found that human ATN is also characterized by ated as previously described (45). Mice that were heterozygous for Crry
alternative pathway activation along the proximal tubule (15). (Crry+/–), littermate controls, and C57BL/6J mice were used to test the
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effects of Crry deficiency since homozygous deficiency is lethal in utero
(45). Only male mice were used in this study because they demonstrate a
higher level of complement activity and are more vulnerable to complement-mediated renal injury (32). Sprague-Dawley rats were used for isolation of renal basolateral and brush border membranes and for immunogold labeling. The animals were housed and maintained in the University
of Colorado Center for Laboratory Animal Care in accordance with the
NIH Guidelines for the Care and Use of Laboratory Animals. The study
protocol was approved by the University of Colorado Health Sciences Center Animal Care and Use Committee.
Antibodies and primers. The following antibodies were used for
immunofluorescence: FITC-conjugated goat anti-mouse C3 (Cappel; MP
Biomedicals) diluted 1:50 with PBS, rat anti-mouse Crry (BD Biosciences —
Pharmingen) diluted 1:150, rabbit anti-human C3d (Dako) diluted 1:150,
mouse anti- Na/K-ATPase α-1 (Upstate USA Inc.) at a concentration of
0.5 μg/ml, rabbit anti-mouse collagen type IV (Chemicon International)
diluted 1:400. FITC-conjugated Arachis hypogaea (Sigma-Aldrich) was used
as a distal tubule marker (46). A polyclonal rabbit anti-DAF antibody and
a mouse anti-CD59 mAb (a generous gift of S. Tomlinson, Medical University of South Carolina, Charleston, South Carolina, USA) were diluted
1:300. To stain F-actin, Alexa Fluor 350 phalloidin (Invitrogen Corp.) was
diluted 1:40. For secondary antibodies, FITC-conjugated anti-rat IgG,
rhodamine-conjugated anti-rabbit IgG, and FITC-conjugated anti-mouse
IgG (Cappel; MP Biomedicals) were used at dilutions of 1:100, and Alexa
Fluor 488–conjugated goat anti-rabbit IgG was used at a dilution of 1:400
(Invitrogen Corp.). Two mAbs were used as complement protein inhibitors.
The mAb 5D5 (47) was used to inhibit the function of cell-surface Crry,
and mAb 1379 (48) was used to block mouse alternative pathway activity.
Fab fragments of 5D5 were also made using papain-agarose (MP Biomedicals) according to the manufacturer’s instructions.
For Western blot analysis, a peroxidase-conjugated goat anti-mouse C3
(Cappel; MP Biomedicals) was used at a dilution of 0.3 μg/ml. A polyclonal
antibody to Crry (23) and a polyclonal anti–type IIa Na/Pi cotransporter
antibody (49) were used at dilutions of 1 μg/ml, followed by incubation
with peroxidase-conjugated goat anti-rabbit IgG (Sigma-Aldrich).
Induction of ischemic ARF. Mice weighing 20–25 g were anesthetized with
300 μl 2,2,2-Tribromoethanol (Sigma-Aldrich) injected intraperitoneally.
After the mice were anesthetized they were placed on a heating pad to
maintain their body temperature during surgery. Laparotomies were then
performed, and the renal pedicles were located and isolated by blunt dissection. The pedicles were clamped with surgical clips (Miltex Inc.), and occlusion of blood flow was confirmed by visual inspection of the kidneys. The
clamps were left in place for 24 minutes and then released. This time of
ischemia was chosen to obtain a reversible model of ischemic ARF with a
minimum of vascular thrombosis and to avoid animal mortality. For experiments comparing Crry+/– mice with Crry+/+ controls, an ischemic time of 20
minutes was used. The shorter ischemic time was chosen because it causes
milder injury, allowing for detection of mouse strains with greater susceptibility to I/R injury. The kidneys were observed for approximately 1 minute
to ensure blood reflow, then fascia and skin were sutured with 4-0 silk (U.S.
Surgical). Sham surgery was performed in an identical fashion, except that
the renal pedicles were not clamped. The mice were volume resuscitated
with 0.5 ml of normal saline and kept in an incubator at 29°C to maintain
body temperature. After 0, 2, 6, 24, or 48 hours of reperfusion the mice were
anesthetized, and blood was obtained by cardiac puncture. Laparotomy was
performed and the kidneys were harvested.
SUN measurements. SUN was determined for each mouse using a Beckman Autoanalyzer (Beckman Coulter).
Renal morphology. After the kidneys were removed from the mice, sagittal sections were fixed in 4% paraformaldehyde. After being embedded in
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paraffin, 4-μm sections were cut and stained with periodic acid–Schiff. The
sections were evaluated by a renal pathologist (D. Ljubanović) in a blinded
fashion. The cortex and outer stripe of the outer medulla were assessed
for epithelial necrosis, loss of brush border, tubular dilatation, and cast
formation. At least 10 fields (magnification, ×400) were reviewed for each
slide, and the percentage of tubules displaying these findings was determined. Kidney sections were scored as follows based on the percentage of
affected tubules: 0, none; 1, less than 10%, 2, 10–25%, 3, 26–45%, 4, 46–75%,
5, greater than 75%.
Immunofluorescence and in situ hybridization. For immunofluorescence,
sagittal sections of the kidneys were snap frozen in OCT compound
(Sakura Finetek). Sections (4 μm) were cut with a cryostat and stored at
–70°C. The slides were later fixed with acetone and incubated with the
primary antibodies. After hybridization with antibodies was complete the
slides were counterstained with hematoxylin (Vector Laboratories). Tissue
sections were incubated with secondary antibodies alone to ensure the
specificity of antibody binding.
To detect the presence of Crry in the urine, immunofluorescence was
performed on urine sediments as previously described (24). Upon sacrifice
after 6 hours of renal reperfusion, urine was expressed from the bladder
and collected at the tip of the urethra. Urine was centrifuged at 4°C for 10
minutes at 15,996 g. The pellets were then fixed for 1 hour at room temperature in 3% paraformaldehyde in PBS (pH 7.4). The sediment was then
washed 3 times in PBS for 5 minutes and recentrifuged for 5 minutes at
15,996 g. The pellets were incubated for 10 minutes in 0.1% Triton X-100
(Sigma-Aldrich) in PBS. Nonspecific binding was blocked with 2% BSA in
PBS for 1 hour. The pellets were then incubated with rat anti-mouse Crry
and Alexa Fluor 350 phalloidin. To ensure that antibody binding was specific, anti–secondary antibody alone was used as a control.
Imaging was performed on a Nikon T2000 inverted fluorescent microscope and slidebook software (version 3.0; Intelligent Imaging Innovations
Inc.). Intensity histograms were obtained using a Zeiss LSM 510 Meta confocal microscope running Zeiss software version 3.2 Service Pack 2.
To examine kidneys for the local production of C3, 16-μm kidney sections were fixed for 15 minutes in cold 4% paraformaldehyde. The sections
were then hybridized with a digoxin-labeled antisense probe to mouse C3
(Table 1) according to the manufacturer’s instructions (GeneDetect.com).
The bound probe was detected using alkaline phosphatase–labeled antidigoxigenin Fab fragments and NBT/BCIP tablets (Roche Diagnostics
Corp.). Digoxin-labeled sense probe to mouse C3 was used to confirm the
specificity of the binding.
Immunogold labeling of Crry. Rat kidneys were fixed by perfusion with 2%
formaldehyde and 0.1% glutaraldehyde in 0.1 M sodium cacodylate, pH
7.35, as previously described (50). The samples were dehydrated and embedded in LR Gold resin (Polysciences Inc.). Ultrathin sections were then prepared using nickel grids and stained for Crry. The grids were floated on
droplets of PBS (10 minutes), 10% whole goat serum (10 minutes), and
either droplets of rabbit anti-Crry at a dilution of 20 μg/ml or nonimmune
rabbit serum diluted 1:150 (45 minutes). The grids were washed using
droplets of PBS for a total of 20 minutes, after which each was floated
on 10 μl of goat anti-rabbit IgG Fab2 conjugated to 10-nm gold particles
(Ted Pella Inc.). After washing the grids with PBS, they were stained for
6 minutes with 2% uranyl acetate, washed with water, and air dried. The
sections were then viewed using a Tecnai G2 microscope (FEI Co.). After
identifying PTECs, images were taken at a magnification of ×18,500 in the
apical and basal regions of the cells, and the number of gold particles seen
in each view were counted.
Western blot analysis. Renal tissue was homogenized in RIPA lysis buffer
containing 1% Triton X-100, 0.5% deoxycholic acid, 150 mM NaCl, 20 mM
β-glycerophosphate, 20 mM Tris-HCl (pH 8.0), 5 mM EGTA, 3 mM MgCl2,
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0.1% SDS, 1 mM DTT, 50 μM Na3VO4, and 1 tablet of complete, EDTA-free
protease inhibitor cocktail (Roche Diagnostics Corp.). Homogenates were
centrifuged at 15,996 g for 15 minutes at 4°C, and the supernatant was collected. Brush border and basolateral membranes from rat renal cortical tissue were isolated as previously described (51). Briefly, kidneys were placed
in cold isolation buffer containing 300 mM mannitol, 5 mM EGTA, 0.1
mM PMSF, and 18 mM Tris (pH 7.4). Thin cortical sections were obtained
and homogenized. Brush border and basolateral membranes were then isolated by differential centrifugation, magnesium precipitation, and use of a
discontinuous sucrose gradient (52). To isolate triton-soluble and -insoluble protein fractions, kidneys were homogenized in a solution containing
0.1% Triton X-100, 20 mM HEPES, 120 mM KCl, 12 mM NaCl, 1.62 mM
MgSO4, 1 mM EDTA, 0.35 mM CaCl2, and 1 tablet of complete, EDTAfree protease inhibitor cocktail (Roche Diagnostics Corp.). Samples were
centrifuged at 35,000 g for 14 minutes at 4°C to separate the soluble and
insoluble fractions. Because approximately two-thirds of cellular proteins
are triton soluble (53), the insoluble pellet was resuspended at half the volume of buffer used for the initial homogenization. Protein concentrations
for all of the samples were determined using the Bio-Rad protein assay
(Bio-Rad Laboratories). Protein (50 μg) for each sample was resolved by
electrophoresis with a 10% Bis-Tris polyacrylamide gel (Invitrogen Corp.)
and transferred to a nitrocellulose membrane. The membrane was probed
with antibody to Crry and visualized using a chemiluminescence detection
kit (Amersham Biosciences).
Reverse transcription polymerase chain reaction. Kidneys were obtained from
unmanipulated mice and mice subjected to ischemia and variable times
of reperfusion. The outer medullary region of the kidney was manually
dissected away from the inner medulla and the outer cortex, and RNA
was isolated using TRIzol reagent (Gibco; Invitrogen Corp.). cDNA was
generated from 3 μg RNA using MuLV Reverse Transcriptase (Applied
Biosystems). Quantitative real-time PCR for C3, factor B, and factor H
was then performed using the designated primers (Table 1). Appropriate primers were designed using Beacon Designer software (version
4.0; PREMIER Biosoft International). Samples were prepared using iQ
Sybergreen Supermix (Bio-Rad Laboratories) and the iCycler iQ detection system (Bio-Rad Laboratories). Triplicate reactions for each sample
were performed using the target primers and using cyclophilin primers
to provide an internal control. Conventional PCR for Crry was performed
in a GeneAmp 9700 PCR system (Applied Biosystems) after using cDNA
from an unmanipulated kidney to determine the linear range of amplification. Control PCR was performed using primers for glyceraldehyde3-phosphate dehydrogenase. PCR products were run on 2% agarose gels
and visualized with ethidium bromide.
In vitro assay of complement inhibition by Crry on PTECs. Boston University
mouse proximal tubular cells (BUMPT cells) were generously provided
1. Thurman, J.M., Ljubanovic, D., Edelstein, C.L.,
Gilkeson, G.S., and Holers, V.M. 2003. Lack of
a functional alternative complement pathway
ameliorates ischemic acute renal failure in mice.
J. Immunol. 170:1517–1523.
2. Zhou, W., et al. 2000. Predominant role for C5b-9
in renal ischemia/reperfusion injury. J. Clin. Invest.
105:1363–1371.
3. De Vries, B., et al. 2003. Complement factor C5a
mediates renal ischemia-reperfusion injury independent from neutrophils. J. Immunol. 170:3883–3889.
4. Pratt, J.R., et al. 2003. Nontransgenic hyperexpression of a complement regulator in donor kidney
modulates transplant ischemia/reperfusion damage, acute rejection, and chronic nephropathy. Am.
J. Pathol. 163:1457–1465.
5. Park, P., et al. 2002. Injury in renal ischemia-reperfusion is independent from immunoglobulins

to us by J. Schwartz (Boston University Medical Center, Boston, Massachusetts, USA). This is a mouse PTEC line that was established from the
immortoMouse (54). Cells were grown to confluence in DMEM supplemented with 10% fetal bovine serum, penicillin/streptomycin, and 0.2
U/ml IFN-γ (PeproTech Inc.). After the cells reached confluence they were
changed to 1:1 DMEM/Hams F12 supplemented with 5 mg/l transferrin
(Invitrogen Corp.), 50 nM hydrocortisone (Sigma-Aldrich), and 5 mg/l
insulin for 2 days. As a source of complement components, 10% serum
from C57BL/6J mice was added to a reaction mix containing 5 mM MgCl2
and 10 mM EGTA in PBS. Some of the cells were also treated with 100
μg/ml 5D5, an inhibitory mAb to Crry (47), or the same concentration of
control rat IgG1 (Sigma-Aldrich). To confirm that the effects of 5D5 were
due to its inhibitory activity and a nonspecific effect of antibody binding, 70 μg 5D5 Fab were added to cells with serum and compared with
cells treated with 5D5 IgG. Another group of cells was treated with 5D5
after preincubating the mouse serum with 40 μg 1379, an inhibitory mAb
to mouse factor B (an essential component of the alternative pathway).
Cells were incubated for 10 minutes, and supernatant was then tested for
LDH content. LDH was measured by the Cytotox-ONE assay (Promega)
according to the manufacturer’s instructions, and the results were read
on a Wallac 1420 fluorescence plate reader (PerkinElmer and Analytical
Sciences Inc.) with an excitation wavelength of 530 nm and an emission
wavelength of 590 nm.
Statistics. Multiple-group comparisons were performed using ANOVA
with post-test according to Newman-Keuls. Comparison between the
control and Crry+/– groups was performed with the Mann-Whitney test. A
P value of less than 0.05 was considered statistically significant. Results are
reported as mean ± SEM.
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